Preliminary Agenda

• What has market growth looked like over the past year? What’s projected for 2026?
• Has the market reached maturity? Is the market oversaturated?
• Will the market see consolidation in the near future?
• What new products are emerging to disrupt the market? Is insurance still on the rise?
• What type of cases are the most prominent? Single cases, portfolios, monetization, acceleration?
• How is the Mass Tort market impacting the broader funding arena?
• What’s keeping some investors on the sidelines and what can be done to change that?

• How are funding and insurance working together to lower rates on good risk?
• What solutions are available to de-risk and monetize litigation and arbitration?
• How has the use of insurance impacted pricing and financing options for funding?
• What will insurance cover? What won’t it cover? Is all of this black and white?
• How are insurance policies priced? How much coverage do you need?
• What are funders concerned about?
• Is the increase in “nuclear verdicts” causing concern in the insurance sector and is this impacting insurance related to funding?
• What are the macro-economic impacts on rising insurance and business costs

• What recent legislative action is threatening to restrict funding? What court cases and legal decisions are impacting funders?
• What are current concerns around disclosure and transparency?
• What ethical conflicts of interest are regulators targeting?
• Are there ethical concerns around the participation of private equity and institutional investors in the legal market?
• Is more regulation the answer? Where is regulation important and where is it limiting opportunity?
• What should we make of claims regarding foreign financing and national security concerns?

• Has the funding of Mass Tort plateaued? What does the future hold?
• Is the Mass Tort industry becoming increasingly vertically integrated?
• What new and emerging fund structures are we seeing?
• What are funders using to evaluate deals? What are expected returns at this point?
• Are funders using technology and AI to evaluate and mitigate risk?
• Exploring ethical concerns around mass tort advertising and case acquisition
• How are Mass Tort deals priced? What is the risk profile for investors?
• What is the role of insurance in the Mass Tort markets

• What’s behind the increase in larger law firms entering the fray and getting deals done? What can be done to continue this trend?
• How can Litigation Funding be used to drive increased profits and grow a practice?
• How are companies leveraging their legal claims or pending litigation to secure immediate capital?
• Will corporate monetization materialize?
• Exploring non-recourse financing
• What has been successful? What has been a struggle? How have cases been successfully tried in the current market?
• What concerns do law firm general counsel typically identify for funding deals?
• How are funders offering bespoke solutions tailored to corporate clients?

• Are there enough quality cases to support the amount of capital in the market?
• What is the preferred investment structure? Sole investor? Fund? Public Company? Co-investments? Others?
• What are the most promising emerging funding opportunities?
• What are the main concerns from investors? Lack of control? Time to resolution? Lack of track record? Public perception?
• What criteria should be used when evaluating investments in funders?
• How are the potential for substantial returns and “nuclear verdicts “impacting investment appetite?
• What kinds of returns can investors reasonably expect in today’s market?
• Using debt and equity instead of traditional capital raising

Grow your network by participating in our curated speed networking session suitable for all conference delegates. This is a unique opportunity to meet new contacts, strengthen business opportunities, broaden perspectives and generate new ideas.